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Abstract
Background: Several subtypes of HIV-1 circulate in infected people worldwide, including subtype
B in the United States and subtype C in Africa and India. To understand the biological properties
of HIV-1 subtype C, including cellular tropism, virus entry, replication efficiency and cytopathic
effects, we reciprocally inserted our previously characterized envelope V3–V5 regions derived
from 9 subtype C infected patients from India into a subtype B molecular clone, pNL4-3. Equal
amounts of the chimeric viruses were used to infect T-lymphocyte cell lines (A3.01 and MT-2),
coreceptor cell lines (U373-MAGI-CCR5/CXCR4), primary blood T-lymphocytes (PBL) and
monocyte-derived macrophages (MDM).
Results: We found that subtype C envelope V3–V5 region chimeras failed to replicate in T-
lymphocyte cell lines but replicated in PBL and MDM. In addition, these chimeras were able to infect
U373MAGI-CD4+-CCR5+ but not U373MAGI-CD4+-CXCR4+ cell line, suggesting CCR5
coreceptor utilization and R5 phenotypes. These subtype C chimeras were unable to induce
syncytia in MT-2 cells, indicative of non-syncytium inducing (NSI) phenotypes. More importantly,
the subtype C envelope chimeras replicated at higher levels in PBL and MDM compared with
subtype B chimeras and isolates. Furthermore, the higher levels subtype C chimeras replication in
PBL and MDM correlated with increased virus entry in U373MAGI-CD4+-CCR5+.
Conclusion: Taken together, these results suggest that the envelope V3 to V5 regions of subtype
C contributed to higher levels of HIV-1 replication compared with subtype B chimeras, which may
contribute to higher viral loads and faster disease progression in subtype C infected individuals than
other subtypes as well as rapid HIV-1 subtype C spread in India.
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Introduction
The steepest increase in new cases of human immunode-
ficiency virus type 1 (HIV-1) infection has taken place in
South America [1] and South/Southeast Asia [2], of which
India is experiencing a rapid and extensive spread of infec-
tion. National surveys in India have shown that the spread
in India is primarily heterosexual in the metropolitan and
coastal cities, and via intravenous drug use in the North-
east bordering Myanmar [3,4]. The HIV-1 sequences ana-
lyzed from different cohorts from several regions in India
suggests that HIV-1 subtype C is the predominant subtype
found in India [3-8]. It has also been shown in several
African and South American studies that subtype C rap-
idly predominates over all the other HIV-1 subtypes after
being introduced in those populations [1,9], suggesting
that subtype C may soon become the prevalent subtype
worldwide. However, the biological properties of HIV-1
subtype C viruses that may influence its rapid spread are
not known.
HIV-1 envelope gp120 interacts with CD4 receptor and
CXCR4 or CCR5 coreceptor [10-13] on T lymphocytes,
monocytes/macrophages and other cell types [11,14,15]
to enter target cells. Analysis of env gp120 sequences from
a large number of HIV-1 isolates shows that gp120 is
made up of five variable regions (V1 to V5) that are inter-
spersed with conserved regions [16]. The potential patho-
genic region of HIV-1 presumably lies within these
variable regions, especially in the V3 region comprising of
35 amino acids arranged in a disulphide loop involving
two cysteines [10]. The hypervariable region 3, the V3
region, is functionally important in virus infectivity [17-
19], virus neutralization [13,20-22], replication efficiency
and host cell tropism [10,23], whereas the V1–V2 regions
influence replication efficiency in macrophages by affect-
ing virus spread [24,25]. In addition, the variable loops V4
and V5 of gp120 are less flexible regions of the proteins
and may play roles in CD4 binding and neutralizing anti-
body responses [26,27]. The mechanisms by which the V3
domain and other regions of the env glycoprotein control
cell tropism were described by identifying two distinct co-
receptors, fusin (CXR4) and CCR5, for the entry of T-lym-
photropic and macrophage-tropic HIV-1, respectively
[11,15]. The region responsible for determining corecep-
tor utilization was examined by Choe et al., [12] and
showed that the V3 region was responsible for interacting
with this co-receptor. Several studies have shown that a
reciprocal transfer of an HIV-1 R5 clones' V3 region into
an X4 molecular clone changed its tropism to allow infec-
tion and replication in macrophages [10,19,23,28-30].
However, most of the data on viral infectivity, coreceptor
utilization, replication efficiency and cytopathic effects
have been obtained from HIV-1 subtype B, and very lim-
ited information is available on subtype C viruses, espe-
cially those from India.
In this study, we have characterized the biological proper-
ties of HIV-1 subtype C envelope V3 to V5 regions by con-
structing chimeric recombinant viruses containing
subtype C envelope V3–V5 regions from nine infected
patients from India [5] into subtype B infectious molecu-
lar clone, pNL4-3. We show that the envelope V3–V5
regions of HIV-1 subtype C changed the tropism of HIV-1
NL4-3 from X4 to R5 and contributed to the increased
virus entry and replication efficiency in primary blood T-
lymphocytes (PBL) and monocyte-derived macrophages
(MDM) compared with subtype B viruses. This higher rep-
lication efficiency of subtype C compared with subtype B
may contribute to a higher viral load and faster disease
progression in patients infected with HIV-1 subtype C
viruses in the Indian population.
Results
Characterization and comparison of subtype C envelope 
V3–V5 chimeras' sequences with known isolates
We confirmed the reciprocal insertion of the sixteen enve-
lope V3–V5 region sequences (Fig. 1) from nine subtype
C infected patients' isolates from India (Table 1) that were
sequenced before [5] into pNL4-3 by nucleotide sequenc-
ing. Two clones were selected from each patient for recip-
rocal insertion. The patients harbored various stages of
HIV disease (I to IVE) based on the 1987 CDC classifica-
tion. We also compared the subtype C env V3 to V5
regions chimeras with HIV-1NL4-3, HIV-1BaL and a known
env V3–V5 region sequence of subtype C (Fig. 1). All the
subtype C env V3–V5 clones showed a greater similarity to
the R5 virus HIV-1BaL than HIV-1NL4-3. The amino acids
critical for the R5 phenotype, including the Y at position
283 and E or D at position 287 were present in all subtype
C clones. The amino acid H at position 275 seen in HIV-
1Ba-L which is also important for determining R5 tropism
was present only in the clones from patient 17 (clones 171
and 173). The amino acid sequences between positions
310–315 and 350–373 were significantly different from
HIV-1NL4-3 clone but were very similar to the previously
known sequence of subtype C envelope region. It is inter-
esting to note that a critical glycosylation site, which
includes the first cysteine of the V3 loop, was mutated in
all the clones except those obtained from patient 17 and
5 (clones 171, 173, 512, 514). The sequence analysis of all
the clones indicate that these clones are different from
HIV-1NL4-3 envelope sequences but very similar to enve-
lope sequences from known subtype C clones and to R5
tropic viruses such as HIV-1BaL.
Computational prediction of coreceptor usage using V3 
amino acid sequence of subtype C chimeras
We also used the Position Specific Scoring Matrix (PSSM)
bioinformatics tool (X4/R5) to predict coreceptor usage
by the Subtype C patient env V3–V5 region sequences [31]
and calculated scores for each clone are shown in Table 2. 
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Table 1: Patient demographics, possible source and risk factor of transmission and CDC disease classification.
Patient Code Chimeras Number Age/Sex Possible source Risk factor CDC classification
AP.17 171, 173 27/M Africa/Germany Promiscuous 
heterosexual
IV-C, D
AP.18 182, 183 14/M Punjab (India) Blood transfusion IV-E
AP.2 221A 20/M Dubai/Punjab Promiscuous 
heterosexual
II
AP.28 282, 284 28/M Kolkata (India) Truck driver IV
AP.33 331, 334 26/M Punjab Hemophiliac I
AP.4 452, 454 25/M Mumbai (India) Promiscuous 
heterosexual
IV-C
AP.5 512, 514 23/F Africa/Germany Spouse with AIDS II
AP.6 639 27/M Punjab Promiscuous 
heterosexual
II
AP.10 1011, 1014 25/M Mumbai Blood transfusion IV-C
CDC-Center for Disease Control and Prevention
Comparison of envelope (V3 to V5 regions) from subtype C chimeras with subtype B (X4 and R5) and C envelope sequencesFigure 1
Comparison of envelope (V3 to V5 regions) from subtype C chimeras with subtype B (X4 and R5) and C envelope sequences. 
The sequences of subtype C env chimeras used in this study were analyzed by performing multiple sequence alignment with 
parental clone HIV-1NL4-3 as a reference and HIV-1BaL and known HIV-1 subtype C envelope regions for comparison. Subtype C 
chimeras are designated by numbers. Dots indicate a match with the reference sequence whereas substitutions are indicated 
by the single letter code for the changed amino acid. Gaps are shown as dashes. Structural elements of the envelope are indi-
cated by spanning arrowheads and glycosylation sites are indicated by asterisk. Amino acid positions are indicated to denote 
the amino acid numbers of the complete envelope gp120.
*** *** V3 ***  ***           ***
NL43  RSANFTDNAK TIIVQLNTSV EINCTRPNNN TRKSIRIQRG PGRAFVTIGK -IGNMRQAHC NISRAKWNAT LKQIASKLRE QFGNNKTIIF KQSSGGDPEI VTHSFNC
      BAL  ..E...N... .......E.. .......... .....H.--. .....Y.T.E I..DI..... .L......D. .NK.VI.... ...-....V. .H........ .......
   HIV-1C  ..E.L..... ....HF.E.. Q......G.. ....V..--F ..Q..YAT.D I..DI.K.Y. ...KGE.AKV MQKVTG..K. H.P-K.N.T. QPP....L.. T......
      171  ..E.L.N... ......VEP. T......... .....H.--. ..Q..YAT.D L..DT.K.Y. TVNGTN..R. .HKV.EQ.GR H.--.R..N. TKP....L.. T......
      173  ..E.L.N... ......VEP. T......... .....H.--. ..Q..YAT.D L..DT.K.Y. TVNGTN..R. .HKV.EQ.GR H.--.R..N. TKP....L.. T......
      182  ..E.L...V. ....H.DQP. ..V.I..... ....V..--R ..QT.YAT.D I..DI.K.Y. ...E....E. .QKVGK..A. Y.P-....N. TL.A...L.. T......
      183  ..E.L...V. ....H.DQP. ..V.I..... ....V..--R ..QT.YAT.D I..DI.K.Y. ...E....E. .QKVGK..A. Y.P-....N. TL.A...L.. T......
      221  ..E.L.N.V. ....H..Q.. ..M....... .......--. ..QT.YAT.D I..DI.R... ...GD...E. .QRVGK..P. H.P-....K. AS.....L.. T......
      282  ..E.L.G.V. ....H..Q.. ..V....H.. .......--. ..QT.YAT.E I..DI..... ...GD...E. .QRVGK..A. H.P-....K. NS.....L.. T......
      284  ..E.L.G.V. ....H..Q.. ..V....H.. .......--. ..QT.YAT.E I..DI..... ...GD...E. .QRVGK..A. H.P-....K. NS.....L.. T......
      331  ..D.L.N.VN ....H..Q.A D.V....S.. .......--. S.QT.Y.T.E I..DI..... ...ED..DE. .QRVGQ..A. H.P-....K. AS.....L.. T......
      334  ..D.L.N.VN ....H..Q.A D.V....S.. .......--. S.QT.Y.T.E I..DI..... ...ED..DE. .QRVGQ..A. H.P-....K. AS.....L.. T......
      452  ..E.L.N... I...H.SQ.. ..V....... .......--. ..QT.YAT.D I..DI.E.Y. ...QD...E. .QRVSK.VSR L.P-....K. NS.....L.. T......
      454  ..E.L.N... I...H.SQ.. ..V....... .......--. ..QT.YAT.D I..DI.E.Y. ...QD...E. .QRVSK.VSR L.P-....K. NS.....L.. T......
      512  ..E.L.N... ......VEP. K......... ....V..--. ..Q..YAT.E I..DI.K.Y. TVN.TD..R. .HKV.EQ..Q H.N-...... TN.....L.. T.L....
      514  ..E.L.N... ......VEP. K......... ....V..--. ..Q..YAT.E I..DI.K.Y. TVN.TD..R. .HKV.EQ..Q H.N-...... TN.....L.. T.L....
      639  ..E.P.N.I. ....H..Q.. ..V....... .......--. ..QT.YAT.D I..DI..... ...KN...E. .QRVGK..P. H.P-....K. TS.....L.. T......
     1011  ..E.L.N.V. ....H..Q.. ..V....... .......--. ..QT.YAT.E I......... ...EK...E. .QRVGK..P. H.P-.R..K. AS.....L.. T......
     1014  ..E.L.N.V. ....H..Q.. ..V....... .......--. ..QT.YAT.E I......... ...EK...E. .QRVGK..P. H.P-.R..K. AS.....L.. T......
V4                                                                     V5
*** *** ** *   *** *** ** *
NL43  GGEFFYCNST QLFNSTWFNS TWSTEGSNNT EGSD-TITLP CRIKQFINMW QEVGKAMYAP PISGQIRCSS NITGLLLTRD GG---NNNNG SEIFRPGGGD MRDNWR
      BAL  .......... .......N-- --V..E.... VENN...... .....I.... ....R..... ..R....... .......... .....PED.K T.V....... ......
   HIV-1C  R.......TS E...G----- -YN--.TD.N SN--K....L .....I..T. ....R.I... ..A.N.I.I. .......... ...KT.DT.D T........N .K....
      171  .......DTS R......NWT GTNIKSTG.D N.VNGN.... .K.R.I.R.. .R..Q..... ..Q.V.N.L. .......... ....NS-S.. I......... ......
      173  .......DTS R......NWT GTNIKSTG.D N.VNGN.... .K.R.I.R.. .R..Q..... ..Q.V.N.L. .......... ....NS-S.. I......... ......
      182  ........T. G...G.YNST -YMPN.TASN SN--S...I. .....I.... ....R..... ..A.N.T.K. .......V.. .....SLTS. T......... ......
      183  ........T. G...G.YNST -YMPN.TASN SN--S...I. .....I.... ....R..... ..A.N.T.K. .......V.. .....SLTS. T......... ......
      221  R.......TS N.....YMPT -YMPN.TESG SN--S....L .....IV.L. ....R..... ..E.N.T.K. .......V.. .....LKS.S T......... ......
      282  R.......TS K...G.YMPT -YMPN.TESN S---SI..I. .....I.... ....R.I... ..E.N.T.K. ....I..V.. ..EGDTIK.D T......... ......
      284  R.......TS K...G.YMPT -YMPN.TESN S---SI..I. .....I.... ....R.I... ..E.N.T.K. ....I..V.. ..KGDTIK.D T......... ......
      331  R.......TS G...G----T -YMPN.TKSN SS--SI..I. .....I.... ....R..... .VE.N.T.N. T......... ...IGTEQ.D T......... ......
      334  R.......TS G...G----T -YMPN.TKSN SS--SI..I. .....I.... ....R..... .VE.N.T.N. T......... ...IGTEQ.D T......... ......
      452  R.......TS G....----T -YW.NATKSN SS--S.F.IY .....IV... ....Q..... ..A.N.T.K. .......V.. ...SGQDGPK DLQTWRRRYE GQLE..
      454  R.......TS G....----T -YW.NATKSN SS--S.F.IY .....IV... ....Q..... ..A.N.T.K. .......V.. ...SGQDGPK DLQTWRRRYE GQLE..
      512  .......HTS G......PWN -----NTQ.S N-HTEN.... .....IVH.. .R..Q..... ..P.V.N.V. .........N ....N..STE E...G....F L.....
      514  .......HTS G......PWN -----STQ.S N-HTEN.... ...R.IVH.. .R..Q..... ..P.V.N.V. .........N ....N..STE E......... ......
      639  R.......TS G...T----- -RLFNSTEGN SS--SF..I. .....I.... ....R..... ..E.N.T.K. ..A....L.. .....IDP.N T......... ......
     1011  R.......TS G....----T -YMPN.TK.N SN--SS..I. .....I.... ....R..... ..A.N.T.K. .......V.. ...EGS--.D T......... ......
     1014  R.......TS G....----T -YMPN.TK.N SN--SS..I. .....I.... ....R..... ..A.N.T.K. .......V.. ...EGS--.D T...G..... ......
-
24
2
-
30
0
-
34
7
-
43
0
-
27
5
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A score of -6.96 was used as a cut off for R5 strains and a
score of -2.88 was used as a cutoff for X4 strains. Most of
these scores were higher than -6.96 especially AP.17
sequence which showed a score of -3.58 clearly below the
cut-off score for X4 strains. Thus, all the clones were
clearly predicted to be R5 tropic. We also used the PSSM
(sinsi) matrix to analyze these sequences and these scores
were in the range of -7.5 to -11.53. This predicts high R5
tropism and a NSI phenotype for all the Indian isolates
examined. Higher numbers of positively charged amino
acids (R/K/H) have been correlated with the likelihood of
CXCR4 use. In all of the Indian sequences in this study,
lower numbers of positive charges, in the range of 5 to 7,
were found (Table 2). Thus, in an in-silico prediction
model, all of the V3–V5 sequences of HIV-1 Indian iso-
lates were predicted to show R5-tropism.
Replication of subtype C chimeric viruses in T-
Lymphocyte cell lines
We first sought to determine whether the subtype C env
chimeras retained the lymphotropic properties of the
parental clone HIV-1NL4-3 by infecting the T cell line
A3.01 with the subtype C chimeric viruses and parental
virus, HIV-1NL4-3. The T-cell line A3.01 expresses CD4
and CXCR4 but no CCR5. Our results showed that the
parental X4 tropic HIV-1NL4-3 productively infected and
replicated in A3.01 over a 27-day infection period.
However, the subtype C chimeras did not replicate in
A3.01 cell line (Fig. 2), suggesting that these chimeras
were no longer T-cell line tropic, unlike the parental
clone. These results further demonstrated that replace-
ment of the V3–V5 regions of envelope of HIV-1NL4-3
with subtype C envelope from infected patients was
responsible for the lack of capacity to use CXCR4 as a
coreceptor for these chimeric viruses. These data also
suggest that the integrated proviruses that were present
in these subtype C infected patient samples were not X4
tropic.
Coreceptor utilization of chimeric subtype C viruses
We then determined the coreceptor utilization of the sub-
type C env chimeras (clone designation in Fig. 1 and Table
1) using U373-MAGI indicator cell lines. These cell lines
express the CD4 receptor in conjunction with either CCR5
or CXCR4 as a coreceptor and can be infected with either
macrophage tropic (R5) or lymphotropic (X4) viruses,
respectively. These cells contain an inducible β-galactosi-
dase reporter driven by HIV-1 LTR that can be used as an
indicator for entry. The known SI isolate HIV-1NL4-3, NSI
isolate HIV-1BaL, and primary isolates were used as con-
trols. As shown in Table 3, all the subtype C env chimeras
were able to infect the U373-MAGI-CCR5 cell line but
were unable to infect the U373-MAGI-CXCR4 cell line.
This data also correlates well with the insilico prediction
Table 2: Prediction of coreceptor usage by Position Specific Scoring Matrix (PSSM) bioinformatics tool that predicts coreceptor 
usage.
Patient/
Clone
Software Score Pred X4 pct R5 pct Geno Pos chg Net Chg Percent
AP.17/171, 
173
X4/R5 -3.58 0 0.47 0.98 SE 6 4 0.83
Sinsi -7.05 0 0.04 0.90 SE 6 4 0.83
AP.18/182, 
183
X4/R5 -6.48 0 0.27 0.95 SD 6 4 0.70
Sinsi -10.73 0 0.04 0.58 SD 6 4 0.70
AP.2/221A X4/R5 -7.83 0 0.22 0.9 SD 7 5 0.57
Sinsi -9.5 0 0.04 0.73 SD 7 5 0.57
AP.28/282, 
284
X4/R5 -8.89 0 0.22 0.88 SE 7 5 0.44
Sinsi -12.12 0 0.01 0.2 SE 7 5 0.44
AP.33/331, 
334
X4/R5 -7.36 0 0.24 0.92 SE 6 4 0.62
Sinsi -10.61 0 0.04 0.51 SE 6 4 0.62
AP.4/452, 
454
X4/R5 -6.50 0 0.27 0.95 SD 5 2 0.67
Sinsi -11.53 0 0.01 0.32 SD 5 2 0.67
AP.5/512, 
514
X4/R5 -9.74 0 0.22 0.82 SE 5 3 0.33
Sinsi -10.69 0 0.01 0.50 SE 5 3 0.33
AP.6/639 X4/R5 -9.06 0 0.22 0.86 SD 6 4 0.48
Sinsi -12.26 0 0.01 0.17 SD 6 4 0.48
AP.10/1011, 
1014
X4/R5 -9.36 0 0.22 0.83 SE 6 4 0.31
Sinsi -11.16 0 0.01 0.04 SE 6 4 0.31
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models and confirms the coreceptor usage of these
viruses. This data suggests that the cloning of these chime-
ras yielded functional envelope regions that can bind
CD4/CCR5 and allow virus entry and production of early
viral genes. As seen by the counts for infectivity of the
MAGI-CCR5 line, the chimeras showed considerable dif-
ferences in infectivity. Some chimeras (171, 173) demon-
strated remarkably high levels of infectivity when
compared to other chimeras and primary isolate controls
indicating an increased rate of entry for these chimeras.
The levels of entry using increasing virus counts (5000
and 10,000 RT counts) during infection showed increased
level of entry for the same chimeras. This shows that the
envelope region of subtype C HIV-1 obtained from the
patient samples shows an R5 phenotype for the virus
infecting the patient. These results also suggest that all the
chimeric viruses obtained could have had different rates
of entry when infecting target cells. This can be attributed
to the differences in the V3 region of the subtype C
chimeric DNA, reflecting the differences found in patient
samples. This also adds to previous work done by others
[4,32,33] showing that the coreceptor utilization of sub-
type C HIV-1 could be predominantly R5 even late in
infection.
Syncytium inducing capacity of subtype C chimeras
We examined the syncytium-inducing ability of the sub-
type C env chimeras by infecting MT-2 cell lines with the
chimeric viruses. Viruses that produce a greater than four
syncytia per field were denoted as syncytium inducing (SI)
phenotype and the viruses that did not induce any syncytia
were called as non-syncytium inducing (NSI) phenotype.
As shown in the Table 3, all of the subtype C V3–V5 region
chimeras failed to produce any syncytia in MT-2 cells and
therefore are of the NSI phenotype (similar to known R5
isolates HIV-1BaL). The control parental virus HIV-1NL4-3
that has a known SI phenotype produced significant levels
of syncytia (at least 10 per field of view). As expected, the
Replication of HIV-1 subtype C env V3–V5 region chimeras in T-lymphocyte (A3.01) cell lineFigure 2
Replication of HIV-1 subtype C env V3–V5 region chimeras in T-lymphocyte (A3.01) cell line. A3.01 cells (1 × 106 cells/well) 
were infected with equal amounts (RT counts) subtype C env chimeras (171 to 1014), parental HIV-1NL4-3 and HIV-1BaL. Virus 
production was measured by reverse transcriptase (RT) assay in culture media harvested every 3 days and the cells fed with 
appropriate media. The results are presented as cpm/ml ± SD of five separate triplicate experiments. The subtype C chimeras 
were unable to replicate in A3.01 cell line.
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R5 viruses used as control also did not produce syncytia in
culture. These data suggest that the envelope sequences
from subtype C infected patient samples render them less
cytopathic as compared to HIV-1NL4-3. We also confirmed
virus production in MT-2 cells and the syncytium forma-
tion correlated to virus production in our partial env (V3–
V5) region chimeras (NSI) and R5 isolates as measured by
RT assay in the culture medium (not shown).
Replication of subtype C chimeras in primary peripheral 
blood T-lymphocytes
Primary T-lymphocytes from peripheral blood express
CD4 and both chemokine receptors, CXCR4 and CCR5.
Since PBL express both CCR5 and CXCR4, they are capable
of supporting the replication of both R5 and X4 tropic
viruses. All the subtype C env chimeras, which did not rep-
licate in A3.01, were able to replicate in PBL showing that
there was no inherent defect in their replication as a results
of the reciprocal insertion of the V3–V5 region from
patient samples (Fig. 3). Although we have demonstrated
the entry of these chimeric viruses using the MAGI cell
experiments, the replication kinetics shown in Figure 3
confirm the capacity of these viruses to enter and replicate
well in culture.
The replication kinetics of subtype C chimeras in PBL
showed that these chimeras replicated at a higher
efficiency as compared to subtype B chimeras (M5g, M7f,
and M1c [34]) and subtype B isolates. Close observation
showed that chimeras 171 and 173 replicated and peaked
much earlier in infection as compared to the other chime-
ras. The V3–V5 region of these chimeras came from a
patient who demonstrated advanced disease (Table 1) [5].
Although some chimeras (284 and 331) peaked relatively
late in infection, they peaked at higher levels than the sub-
type B chimeras. All the subtype C chimeras also replicated
at levels higher than the subtype B primary isolates. The
replication data of the subtype C chimeras (Fig. 3) corre-
lated well with the rate of entry seen in the MAGI cell line
experiments (Table 3). The chimeras that scored higher
numbers in MAGI cell experiments (Table 3) peaked ear-
lier in viral infection experiments (Fig. 3). Comparative
rates of entry of chimeras correspond with the peak of viral
replication, where 171 and 173 with highest level of entry
in MAGI cells showed very early and high peaks and 284
and 331 chimeras with much lower level of entry showed
lower and/or more delayed peaks. It is interesting to note
that chimeras 171, 173, 512 and 514, which retained the
first proximal glycosylation site of the V3 region (Fig 1),
peaked very early (Day 6–9) during replication (Fig 3).
Comparison of the primary isolates of subtype B and sub-
type C also showed that the subtype C primary isolates
replicated better than the subtype B primary isolates.
These data suggest that the envelope V3 to V5 regions of
Table 3: Coreceptor usage by HIV-1 subtype C chimeras in U373-MAGI-CCR5 and U373-MAGI-CXCR4 cell lines.
MAGI-CCR5 MAGI-CXCR4
Infection counts → 5000 10000 5000 10000 Phenotype from 
MT-2
CHIMERA_ No. of blue cells No. of blue cells
171 21 99 - - NSI
173 23 92 - - NSI
182 9 18 - - NSI
183 7 12 - - NSI
221A 0 2 - - NSI
282 9 30 - - NSI
284 2 6 - - NSI
331 13 31 - - NSI
334 1 2 - - NSI
452 23 65 - - NSI
512 1 3 - - NSI
514 1 4 - - NSI
639 1 2 - - NSI
1011 11 26 - - NSI
1014 16 33 - - NSI
2099 (B-R5) 8 19 - - NSI
2101 (B-X4/R5) 5 10 10 21 SI
3041 (C-R5) 7 34 - - NSI
5441 (C-X4) - - 23 38 SI
NSI – non-syncytium inducing, SI – syncytium inducing, - indicate no entry due to lack of blue cells.
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the subtype C influenced the rate of replication of HIV-1
in primary T-lymphocytes and determined the cellular
tropism. Furthermore, there was a direct relationship
between higher viral replication (Fig. 3) and advanced dis-
ease status of the patients (Table 1).
Replication of subtype C chimeras in primary monocyte-
derived macrophages
While primary monocyte derived macrophages (MDM)
express CD4 and CCR5 and a low level of CXCR4, they
support productive infection of R5 but not X4 viruses. As
the subtype C chimeras showed a R5 phenotype (Table 3),
replication kinetics of these chimeras were evaluated in
MDM. Figure 4 shows the replication kinetics of subtype C
chimeras in comparison with primary subtype B and C
controls. The data clearly demonstrated that subtype C chi-
meras replicated better than subtype B viruses. The rate of
replication of the subtype C chimeras in MDM also corre-
lated with the rate of entry of the chimeras in MAGI-CCR5
cell line, further supporting the hypothesis that the
increase in the replication of these chimeras is due to
increase in the rate of entry. Both subtype B (2099) and
subtype C (3041) primary R5 isolates replicated in MDM
and subtype B dual tropic (X4/R5) virus (2101) also
showed adequate replication in MDM. In addition, com-
parison of subtype B and subtype C primary isolates also
showed that the subtype C primary isolates replicated
better than subtype B primary isolates. These data suggest
that the V3 to V5 regions of subtype C influenced increased
replication of HIV-1 in MDM.
Discussion
We have provided evidence regarding the role of the HIV-
1 envelope V3–V5 regions from subtype C infected
patients from India in virus entry, coreceptor utilization
and replication efficiency in primary T-lymphocytes and
macrophages in comparison with those of subtype B
viruses. Our data suggest that the reciprocal insertion of
Replication of HIV-1 subtype C env V3–V5 region chimeras in primary peripheral blood T-lymphocytes (PBL)Figure 3
Replication of HIV-1 subtype C env V3–V5 region chimeras in primary peripheral blood T-lymphocytes (PBL). PBL (1 × 106 
cells/well) were stimulated with PHA and infected with equal amounts (reverse transcriptase counts) of subtype C env V3–V5 
region chimeras, subtype B env V3 region chimeras, primary subtype B isolates, primary subtype C isolates and parental HIV-
1NL4-3. Cells were fed every 3 days with appropriate medium and virus production was measured in the culture supernatant by 
RT assay. The data are presented as cpm/ml ± SD on triplicate experiments and are based on PBL from five different donors.
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HIV-1 subtype C infected patients' envelope V3 to V5
regions [5] into subtype B molecular clone, contributed to
utilization of CCR5 coreceptor (Table 3) as well as higher
levels of HIV-1 entry and replication efficiencies in pri-
mary T-lymphocytes (Fig. 3) and MDM (Fig. 4). The
higher viral replication efficiencies of R5 phenotype of the
chimeras correlated with advanced disease status of the
patients (Table 1). Taken together, the increased replica-
tion capabilities of HIV-1 subtype C in T-lymphocytes and
MDM may contribute to a high viral load, rapid disease
progression, and spread in infected individuals [35,36].
We have demonstrated that subtype C envelope V3–V5
region chimeras showed increased levels of virus entry
that correlated with an increased rate of replication in pri-
mary T-lymphocytes and MDM compared with subtype B
chimeras and subtype B primary isolates. Careful observa-
tion indicates that chimeras with higher rate of entry
peaked earlier during infection in primary cells. Unlike
the lymphotropic (X4) parental clone HIV-1NL4-3, the
subtype C env V3–V5 region chimeras were unable to rep-
licate in T lymphocyte cell lines A3.01 (Fig. 2) and MT-2
(Table 3), suggesting that the chimeras had lost the T-cell
line tropism of the parent clone NL4-3 because of recipro-
cal insertion of the V3–V5 region from subtype C patient
samples. In addition, all of the subtype C env chimeras
failed to produce any syncytia in MT-2 cells (Table 3),
denoting NSI phenotypes, similar to the R5 but not NL4-
3 isolates. Infection of U373-Magi-X4 and U373-Magi-R5
cell lines indicate that all our chimeric viruses and the
control R5-tropic isolate HIV-1BaL, utilized the CCR5 core-
ceptor, whereas the parental HIV-1NL4-3 utilized the
CXCR4 coreceptor (Table 3). These results are consistent
with earlier reports that showed reciprocal insertion of the
V3 region of an R5 isolate into an X4 molecular clone
altered the tropism of an X4 isolate to an R5 phenotype
[10,19,23,28-30].
Our in-silico analysis of the V3 sequences of the subtype
C isolates from India predicted R5 tropism (Table 2). This
Replication of HIV-1 subtype C env V3–V5 region chimeras in primary blood monocyte-derived macrophages (MDM)Figure 4
Replication of HIV-1 subtype C env V3–V5 region chimeras in primary blood monocyte-derived macrophages (MDM). MDM 
(0.5 × 106 cells/well) were infected with equal amounts (RT counts) of subtype C env V3–V5 region chimeras, primary subtype 
B isolates, primary subtype C isolates and HIV-1BaL. Cells were fed every 3 days with appropriate medium and the virus pro-
duction was measured in the culture supernatant by RT assay. The data are presented as cpm/ml ± SD on triplicate experi-
ments and are based on MDM from five different donors.
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also explains why these viruses replicated in primary
blood Tlymphocytes (Fig. 3) but failed to replicate in the
T4 lymphocyte cell lines, A3.01 (Fig. 2) and MT-2 because
primary T-lymphocytes express CCR5, whereas and A3.01
and MT-2 do not. This data further supports the predom-
inance of R5 phenotype in subtype C infected patients
[37,38] and its maintenance during symptomatic AIDS.
Several of the patients that exhibited advanced stages of
HIV disease (Table 1) also harbored R5 phenotype (Table
2, 3), rarely seen in subtype B infected adult patients. In
addition, the chimeras from the patients with advanced
disease status (III, IV) replicated more efficiently than the
less advanced disease patients (I, II) [Table 1, Figs. 3 and
4]. Furthermore, it has also been found that the percent-
age of CD4 T cells expressing CCR5 in Indian adults is
higher than among Caucasian races [39]. It is, therefore,
likely that due to the presence of this larger pool of CCR5
positive CD4 cells, the virus may not need a coreceptor
switch during disease progression.
Our data showed that subtype C V3–V5 region chime-
ras replicated better in primary blood T-lymphocytes
(Fig. 3) and MDM (Fig. 4) compared with subtype B
chimeras, HIV-1NL4-3 and subtype B primary isolates. In
general, there was a correlation between higher virus
entry, earlier replication peaks, and increased replica-
tion efficiencies in primary T-lymphocytes and MDM.
Examination of sequence data published earlier on
these patients [5] and presented in Fig. 1 and Table
show several features of subtype C chimeras, including
number of positive charges, amino acid sequence vari-
ation and number of glycosylation sites. One striking
feature was that the chimeras from patient AP.17 (chi-
meras # 171, 173) and AP.5 (chimeras # 512, 514)
retained the N-linked glycosylation site that includes
the first cysteine residue of V3 loop [10], whereas other
chimeras had mutations in this site, contributing to the
differences in replication efficiencies of these chimeras
(Fig. 3). Our subtype V3–V5 region chimeras were in
close resemblance with subtype C (HIV-1C) with V3
sequences similar to HIV-1BAL (R5), as shown in Fig. 1.
The motif SIHIGPGRALYTTGEIIGDI that is important
for R5 tropism as seen for HIV-1BAL in Fig. 1 was fairly
conserved in our subtype C chimeras contributing to R5
tropism. Similarly subtype C chimeras V4–V5 region
sequences show similarity to subtype C sequence but
variability to subtype B (X4 and R5) sequences. The
difference in amino acid sequences in V3 to V5 regions
in subtype C chimeras as compared to subtype B
sequences may be responsible for increased replication
efficiencies of subtype C chimeras. Further studies on
site directed mutagenesis of the V3–V5 regions and
binding affinity of gp120 to CCR5 and/or gp120
incorporation into chimeric virions might pinpoint the
major difference in replication efficiencies.
While a co-infection in vitro study with more fit subtype B
and less fit subtype C viruses indicates more fitness of sub-
type B over subtype C viruses [40], several in-vivo infection
studies on rhesus macaques have shown that HIV-1 subtype
C env chimeric viruses demonstrate greatly enhanced infec-
tivity [41-43] and replication efficiency as compared to sub-
type B and E viruses [44,45]. Our data on higher levels of
HIV-1 entry and increased replication efficiencies of subtype
C chimeras compared with subtype B viruses is consistent
with the latter in vivo studies [41-43]. Increased replication
efficiency of subtype C viruses has also been attributed to
the presence of an extra NF-κB site in the LTR of subtype C
viruses [46,47]. However, these viruses have shown not
only to replicate efficiently but to also be transmitted and
spread more efficiently than other HIV-1 subtypes [1,9].
During horizontal and vertical transmission subtype C
viruses have been shown to spread more rapidly than other
subtypes due to increased mucosal and vaginal shedding
[36,48,49]. This increased transmission cannot solely be
explained due to increased LTR activity as increased shed-
ding of virus and increased transmission may be attributed
to the envelope gene and others regions and functions of the
virus.
While various HIV-1 subtypes prevalent in different regions
of the world show variability in their replication kinetics
and disease progression in infected individuals [32], HIV-1
subtype C is rapidly spreading and has already become the
predominant subtype worldwide. The data presented in
this paper indicate that HIV-1 envelope V3–V5 region of
subtype C contributes to increased rates of replication as
compared to subtype B. This would also explain higher
viral loads and faster disease progression in patients
infected with HIV-1 subtype C [35] as well as increased
shedding of virus seen in subtype C infected population
[36,48]. Our data shows the HIV-1 subtype C envelope V3–
V5 region may be one of the determinants of increased
virus entry and replication. These results provide another
candidate gene to be responsible for the rapid spread of
HIV-1 subtype C and its ability to dominate in populations
that initially had higher incidence of other subtypes.
Methods
Construction of HIV-1 Chimeras
Sixteen previously characterized envelope V3–V5 region
sequences (Fig. 1) from nine subtype C Indian isolates
(Table 1) [5] were reciprocally substituted into pNL4-3 in
BglII-BglII sites flanking the region. The 650 bp fragment
encompassing the V3–V5 region corresponds to amino
acids 240–439 of gp120 of the HIV-INL4-3 sequence with
the V3-loop positioned between amino acids 267 and 300.
PCR primers were designed to amplify the V3–V5 region
and to replace a similar region in pNL4-3 by engineering a
BglII site at the 3' end at position 7611 corresponding to all
isolates. PCR amplification was carried out using Pfu
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polymerase. The ~600 bp PCR product was digested with
BglII and cloned into pGEM (NL4-3) using the BglII sites
[50]. The BglII-BglII fragment was reciprocally exchanged
into the pGEM plasmid containing the EcoRI-BamHI
fragment as there were no EcoRI or BamHI sites in this a
region in any Indian isolate except AP.5 which contained
an EcoRI site in the sequence. The recombinant clones
were checked by digestion with BglII and the orientation
was confirmed by DNA sequencing using primer
(5'TCAACTGCTGTTAAATGGC3'). Finally, the modified
EcoRI-BamHI fragment containing the sporadic subtype C
Indian isolate V3 to V5 region was reciprocally substituted
into pNL4-3. Two clones were obtained from each patient
sample and these are numbered with numerals of patient
identification number followed by clone number. All the
clones were again checked by digestion with EcoRI/SalI
and BamHI and confirmed by sequencing.
Cell lines and primary cells
HeLa cells, U373-MAGI-CXCR4 and U373-MAGI-CCR5
cell lines were cultured in DMEM with 10% fetal bovine
serum (FBS) and penicillin-streptomycin (Invitrogen).
The MAGI cell media was also supplemented with 0.2 mg/
ml of G418, 0.1 mg/ml of hygromycin B and 1 μg/ml of
puromycin. T-lymphocyte cell lines, A3.01 and MT-2 were
cultured in RPMI 1640 supplemented with 10% FBS and
penicillin-streptomycin. Peripheral blood mononuclear
cells (PBMC) were obtained by single step density gradi-
ent centrifugation with Ficoll-Hypaque (Amersham) from
whole blood of normal donors. The blood collections
were made after informed consent, and were approved by
the Human Subject Ethical committees of International
Center for Genetic Engineering and Biotechnology
(ICGEB) and the Human Subjects Committee of the Uni-
versity of Arizona (Tucson, AZ) and were based on Indian
Council of Medical Research (ICMR) and National Insti-
tutes of Health (NIH) guidelines, respectively. PBMC were
collected, washed twice with cold PBS and centrifuged at
1000 rpm for 10 min to avoid collecting platelets. Primary
monocyte/macrophages and peripheral blood lym-
phocytes (PBL) were separated from PBMC using mag-
netic bead isolation protocols. Monocytes were isolated
by CD14 magnetic bead isolation (Miltenyi biotech)
according to the manufacturer's protocols. The cells
bound to the CD14 bead were used as primary mono-
cytes. The primary monocytes eluted from the CD14 iso-
lation columns were counted and plated in 48 well plates
at 1 × 106 cells/well in RPMI 1640 with 15% human AB
serum (Gemini biotech) and MCSF (Sigma) for 7 days
and were allowed to differentiate into macrophages in this
media. The cells were fed every two days during differen-
tiation. The cells collected as unbound flow through from
the CD14 bead isolation protocol were used as PBL. PBL
were cultured in RPMI 1640 with 10% FBS and penicillin-
streptomycin. PBL were stimulated with 5 μg/ml of PHA
for 24–48 h. The stimulated cells were washed with PBS
and resuspended in RPMI 1640 with 10% FBS and 20 U/
ml of recombinant human IL-2 (Invitrogen).
DNA Transfections
Subtype C chimeric proviral DNAs were transfected in
HeLa cells by electroporation as described before [34] or
by Lipofectamine 2000 (Invitrogen) [51]. For the Lipo-
fectamine method, HeLa cells were grown in DMEM with
10% FBS and penicillin-streptomycin to about 80% con-
fluency. The cells were then split and counted and plated
in a 6-well plate at 105 cells/well in DMEM with 10% FBS
without antibiotics. The cells were transfected the next day
with 3 μg DNA in DNA-lipofectamine complexes as per
manufacturer's procedure. Chimeric viruses were har-
vested by collecting culture supernatant from the wells 72
hrs post-transfections. Virus production was measured by
a reverse transcriptase (RT) assay [34,51].
Infections
A3.01 cells (2 × 106), MT-2 (2 × 106), PBL (1 × 106) and
MDM (0.5 × 106) per well were cultured and infected with
equal amounts of subtype C env region chimeras, subtype
B V3 region chimeras (M5g, M7f, M1c) [34,50], subtype B
and C primary isolates, and virus production was meas-
ured every 3 days. We used two subtype C (3041-R5 and
5441-X4) and two subtype B (2099-R5 and 2101-X4/R5)
primary isolates that were obtained from AIDS Research
and Reference Reagent Program as controls. Briefly,
viruses were adsorbed in A3.01 cells, MT-2 and PBL for 90
min in serum free media at 37°C and 5% CO2. After incu-
bation, 500 μl of appropriate media containing serum
and antibiotics were added. MDM were infected in media
containing serum and polybrene (8 μg/ml) incubated at
37°C and 5% CO2 for 16 hrs. After incubation, the mac-
rophages were washed in PBS to remove polybrene and
resuspended in macrophage culture media.
Coreceptor utilization
U373-MAGI-CXCR4 and U373-MAGI-CCR5 cell lines
were plated at ~6 × 104 cells/well in 24 well plate in com-
plete DMEM with G418-hygromycin-puromycin. Both
cells lines were infected with 5,000 and 10,000 cpm (RT
assay counts) of chimeric subtype C virus and primary iso-
late controls diluted in a total volume of 300 μl of com-
plete DMEM (without antibiotics) with DEAE-dextran
(final concentration 20 μg/ml). Two hours post-
adsorbtion, 1.5 ml of fresh MAGI media was added. To
assess the rate of entry, 40 h post-infection, the medium
was removed and cells were fixed in 1% formaldehyde and
0.2% glutaraldehyde for 5 min. Then, the cells were
washed with PBS and stained for 2 hrs in staining solution
containing 0.2 M potassium ferricyanide, 0.2 M potassium
ferrocyanide, 2 M MgCl2 and 40 μg/ml X-Gal. After
staining, the cells were washed in PBS and resuspended in
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PBS with Sodium Azide. Cells stained blue were counted
immediately and counts were estimated as number of blue
cells per well of infected cells.
Cytopathic effects (MT-2 assay)
The syncytium-inducing ability of the subtype C envelope
chimeras was determined and compared to a known syncy-
tium-inducing (SI) virus (HIV-1NL4-3) and a non-syncytium-
inducing (NSI) viruses (HIV-1BaL and HIV-1Ada-M) by infect-
ing the MT-2 cell line with equal amounts of these viruses.
Syncytium formation was monitored every day in the cul-
tures up to 30 days post-infection. The viruses that formed
more than four syncytia per field of view in the culture were
designated as SI viruses (ACTG protocol), whereas viruses
that failed to induce this number of syncytia in the culture
were termed NSI viruses.
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